{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:07:09Z","timestamp":1792069629456,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Cellex Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jhep.2018.07.019","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T22:31:10Z","timestamp":1533076270000},"page":"194-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Statins: Old drugs as new therapy for liver diseases?"],"prefix":"10.1016","volume":"70","author":[{"given":"Elisa","family":"Pose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwar P","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jhep.2018.07.019_b0005","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium","volume":"29","author":"Endo","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jhep.2018.07.019_b0010","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.116.021407","article-title":"Recent update to the US cholesterol treatment guidelines","volume":"133","author":"Nayor","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2018.07.019_b0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jhep.2018.07.019_b0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0025","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jhep.2018.07.019_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","author":"Rzouq","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jhep.2018.07.019_b0035","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0040","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2018.07.019_b0050","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.29277","article-title":"Statins in cirrhosis\u2014ready for prime time","volume":"66","author":"Tsochatzis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.019_b0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/thx.2005.057976","article-title":"Potential therapeutic role for statins in respiratory disease","volume":"61","author":"Hothersall","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jhep.2018.07.019_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jphs.92.7","article-title":"The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses","volume":"92","author":"Nishibori","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jhep.2018.07.019_b0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjp.0704678","article-title":"Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ","volume":"136","author":"Wagner","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhep.2018.07.019_b0070","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/BF02256431","article-title":"HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages","volume":"10","author":"Huang","year":"2003","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jhep.2018.07.019_b0075","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000143232.67642.7A","article-title":"Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase","volume":"110","author":"Landmesser","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2018.07.019_b0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.pathol.4.110807.092145","article-title":"The pathology of chronic obstructive pulmonary disease","volume":"4","author":"Hogg","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jhep.2018.07.019_b0085","doi-asserted-by":"crossref","first-page":"17036","DOI":"10.1074\/jbc.M210429200","article-title":"Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine\/autocrine loop","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2018.07.019_b0090","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1001\/jama.2013.5732","article-title":"Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease","volume":"309","author":"Thomsen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2018.07.019_b0095","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.amjmed.2013.01.036","article-title":"Statin use and risk of COPD exacerbation requiring hospitalization","volume":"126","author":"Wang","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2018.07.019_b0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.pupt.2011.06.003","article-title":"Statins and outcome after hospitalization for COPD exacerbation: a prospective study","volume":"24","author":"Bartziokas","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.07.019_b0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.chest.2017.02.002","article-title":"The impact of statin drug use on all-cause mortality in patients with COPD","volume":"152","author":"Raymakers","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jhep.2018.07.019_b0110","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pupt.2012.10.008","article-title":"Statins, systemic inflammation and risk of death in COPD: the Rotterdam study","volume":"26","author":"Lahousse","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.07.019_b0115","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","article-title":"Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.07.019_b0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/thoraxjnl-2014-205795","article-title":"Statin use and exacerbations in individuals with chronic obstructive pulmonary disease","volume":"70","author":"Ingebrigtsen","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jhep.2018.07.019_b0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s007010050057","article-title":"Inflammatory cytokines locally elevated in chronic subdural haematoma","volume":"140","author":"Suzuki","year":"1998","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.jhep.2018.07.019_b0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jns.2012.04.015","article-title":"Effects of atorvastatin in the regulation of circulating EPCs and angiogenesis in traumatic brain injury in rats","volume":"319","author":"Wang","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jhep.2018.07.019_b0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2362.2009.02110.x","article-title":"Effect of atorvastatin on microRNA 221\u200a\/\u200a222 expression in endothelial progenitor cells obtained from patients with coronary artery disease","volume":"39","author":"Minami","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jhep.2018.07.019_b0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jns.2014.04.009","article-title":"Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats","volume":"341","author":"Li","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jhep.2018.07.019_b0145","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.metabol.2015.08.002","article-title":"Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Sahebkar","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2018.07.019_b0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1073858410385006","article-title":"Prospects of statins in Parkinson disease","volume":"17","author":"Roy","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.jhep.2018.07.019_b0155","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000095679","article-title":"Statins of different brain penetrability differentially affect CSF PLTP activity","volume":"22","author":"Vuletic","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jhep.2018.07.019_b0160","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","article-title":"Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson\u2019s disease","volume":"29","author":"Ghosh","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.jhep.2018.07.019_b0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1179\/1743132812Y.0000000054","article-title":"Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer\u2019s disease","volume":"34","author":"Kurata","year":"2012","journal-title":"Neurol Res"},{"key":"10.1016\/j.jhep.2018.07.019_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vph.2015.12.005","article-title":"Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass","volume":"80","author":"Ouk","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jhep.2018.07.019_b0175","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3233\/JPD-171113","article-title":"Statins and cognition in Parkinson\u2019s disease","volume":"7","author":"Deck","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.jhep.2018.07.019_b0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phrs.2009.03.010","article-title":"Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson\u2019s disease","volume":"60","author":"Mutez","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhep.2018.07.019_b0185","doi-asserted-by":"crossref","first-page":"e0152564","DOI":"10.1371\/journal.pone.0152564","article-title":"Statin use and the risk of parkinson\u2019s disease: an updated meta-analysis. Ghavami S, ed.","volume":"11","author":"Bai","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2018.07.019_b0190","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.07.019_b0195","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacl.2017.01.001","article-title":"Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia","volume":"11","author":"Chung","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jhep.2018.07.019_b0200","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.1038\/srep12931","article-title":"Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis","volume":"5","author":"Schierwagen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2018.07.019_b0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2018.07.019_b0210","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2013.02.005","article-title":"Simvastatin maintains function and viability of steatotic rat livers procured for transplantation","volume":"58","author":"Gracia-Sancho","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0215","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12876-015-0248-8","article-title":"Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells","volume":"15","author":"Chong","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2018.07.019_b0225","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1476-5381.2008.00043.x","article-title":"Simvastatin protects against cholestasis-induced liver injury","volume":"156","author":"Dold","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhep.2018.07.019_b0230","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fphys.2013.00195","article-title":"Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats","volume":"4","author":"Schierwagen","year":"2013","journal-title":"Front Physiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0240","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/labinvest.2012.106","article-title":"Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats","volume":"92","author":"Klein","year":"2012","journal-title":"Lab Investig"},{"key":"10.1016\/j.jhep.2018.07.019_b0245","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial\u2013stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0250","first-page":"G147","article-title":"Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver","volume":"296","author":"Moreno","year":"2009","journal-title":"Am J Physiol Liver Physiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0255","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.07.019_b0260","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.019_b0265","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","article-title":"Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension","volume":"64","author":"Trebicka","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.07.019_b0270","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/640797","article-title":"Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma","volume":"2010","author":"Tijeras-Raballand","year":"2010","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jhep.2018.07.019_b0280","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1038\/srep14573","article-title":"Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension","volume":"5","author":"Uschner","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2018.07.019_b0285","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317734947","article-title":"Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells","volume":"39","author":"Fujiwara","year":"2017","journal-title":"Tumor Biol"},{"key":"10.1016\/j.jhep.2018.07.019_b0290","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3892\/ijo.2010.892","article-title":"Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK","volume":"38","author":"Relja","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jhep.2018.07.019_b0295","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.019_b0300","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0305","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.019_b0310","first-page":"G407","article-title":"Rationale for the use of statins in liver disease","volume":"312","author":"Schierwagen","year":"2017","journal-title":"Am J Physiol Liver Physiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0315","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.07.019_b0320","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","article-title":"Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection","volume":"63","author":"Yang","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.019_b0330","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.07.019_b0335","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-002-0916-0","article-title":"High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production","volume":"37","author":"Roglans","year":"2002","journal-title":"Lipids"},{"key":"10.1016\/j.jhep.2018.07.019_b0340","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0345","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ open Gastroenterol"},{"key":"10.1016\/j.jhep.2018.07.019_b0350","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.019_b0355","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.07.019_b0360","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis c-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.019_b0365","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2018.07.019_b0370","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/apt.12430","article-title":"Statin use and infections in Veterans with cirrhosis","volume":"38","author":"Motzkus-Feagans","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.07.019_b0375","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.019_b0380","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2018.07.019_b0385","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0390","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.019_b0395","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhep.2018.07.019_b0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.019_b0405","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jhep.2018.07.019_b0410","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12\u2008064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.07.019_b0415","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"SEARCH Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.07.019_b0420","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcp.12182","article-title":"CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores","volume":"77","author":"Albarmawi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2018.07.019_b0425","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2217\/pgs-2016-0199","article-title":"The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition","volume":"18","author":"Jiang","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jhep.2018.07.019_b0430","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.taap.2013.03.019","article-title":"ATP-dependent transport of statins by human and rat MRP2\/Mrp2","volume":"269","author":"Ellis","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jhep.2018.07.019_b0435","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/17425250902976854","article-title":"Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs","volume":"5","author":"Ieiri","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781832275X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781832275X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T16:42:08Z","timestamp":1565282528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781832275X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S016882781832275X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.07.019","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins: Old drugs as new therapy for liver diseases?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}